Jimmy Hwang, MD
Medical Oncology · Charlotte, NCNPI 1487653911
Payments from drug & device makers
Across 205 payments — averaging $6342.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$263K
- E.r. Squibb & Sons, L.L.C.$250K
- AstraZeneca$206K
- Boehringer Ingelheim$173K
- Boehringer Ingelheim Pharma GmbH & Co.kg$142K
- Exelixis Inc.$97K
- plus $170K from 16 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 66 | $263,100 |
| E.r. Squibb & Sons, L.L.C. | 12 | $249,695 |
| AstraZeneca | 16 | $205,568 |
| Boehringer Ingelheim | 5 | $172,734 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 41 | $142,396 |
| Exelixis Inc. | 24 | $97,068 |
| AbbVie | 6 | $54,962 |
| Genentech, Inc. | 5 | $37,517 |
| Bayer | 6 | $20,790 |
| Eli Lilly | 1 | $13,715 |
| Incyte Corporation | 5 | $10,579 |
| Boehringer Ingelheim International GmbH | 2 | $6,941 |
| Ipsen Biopharmaceuticals, Inc | 4 | $6,181 |
| Bristol Myers Squibb | 1 | $4,106 |
| Astellas Pharma Global Development | 1 | $2,704 |
| Jazz Pharmaceuticals Inc. | 1 | $2,632 |
| Array Biopharma Inc | 1 | $2,520 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $2,040 |
| Eisai Inc. | 1 | $1,875 |
| GSK | 1 | $1,600 |
| Deciphera Pharmaceuticals Inc. | 3 | $1,306 |
| Genentech USA, Inc. | 2 | $223 |
How this compares
$1,300,253 in reported general payments places this provider in the 85th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Charlotte
- Antoinette TanCharlotte$14.9M
- Nilanjan GhoshCharlotte$6.3M
- Kathryn MilehamCharlotte$4.7M
- David RizzieriCharlotte$1.8M
- Edward KimCharlotte$1.7M
- Kimberly StricklandCharlotte$1.1M
- Obiageli OgbataCharlotte$861K
- Daniel CarrizosaCharlotte$827K
- Mohamed SalemCharlotte$658K
- Ashley SumrallCharlotte$627K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.